Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

 
Phase: 1
Protocol No.Title
1999LS073MT1999-20 Hematopoietic cell transplantation in children with juvenile myelomonocytic leukemia
2012LS089MT2012-17R:Safety of Nplate® in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant
2013CG078COG ADVL1217: A PHASE 1 STUDY OF AZD1775 (MK-1775, IND# 116495) CONCURRENT WITH LOCAL RADIATION THERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMAS
2013LS081HM2013-24: Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
2014CG023COG ADVL1312 - A PHASE 1/2 STUDY OF AZD1775 (MK-1775 , IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS
2014IS062An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutation (MEK116540)
2014IS090A Phase I/II safety, pharmacokinetic, and pharmacodynamic study of APS001F with flucytosine and maltose for the treatment of advanced and/or metastatic solid tumors.
2014LS020MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl®) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
2015CG012COG ADVL1412 - A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab Additional Title: ADVL1412-Bristol-Myers Squibb Company
2015CG151ADVL1414 - A PHASE 1 STUDY OF SELINEXOR (KPT-330, IND #125052), A SELECTIVE XPO1 INHIBITOR, IN RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS, INCLUDING CNS TUMORS
2015IS075HM2015-18: A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
2015LS057MT2015-46 : A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
2016CG116MK3475-051/ADVL1621 - A Phase I/II Study of Pembrolizumab (MK3475) in Children with Advanced Melanoma or a PDL1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE051) Additional Title: ADVL1621 Merck Sharp and Dohme Corp.
2016CG156COG ADVL1513 - A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
2016IS002A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors (I5B-MC-JGDN)
2016IS005MT2018-04: AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLU®) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMISED CHILDREN LESS THAN 13 YEARS OF AGE, WITH CONFIRMED INFLUENZA INFECTION
2016IS013A Phase I/II Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
2016IS191A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions
2016IS192A Phase 1, Open-Label, Multicenter, Dose escalation study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection to patients with advanced malignancies
2016LS034Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only after 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
2016LS153MT2016-27 Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) with Subcutaneous IL-2 in Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML)
2016LS172A Phase 1b/2 Study of Hypofractionated Radiation (HD-XRT) and Combination Immunotherapy for Refractory Metastatic Melanoma
2016LS186MT2017-14 :Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) with Intraperitoneal Interleukin-2 in Women with Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
2016UC011A Phase IB/II study of nivolumab in combination with ALT-803 in patients with pretreated, advanced or metastatic non-small cell lung cancer
2017CG036COG ADVL1515 - A Phase 1 Study of LY2606368 (prexasertib mesylate monohydrate) (IND#132233) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors Added Title: "ADVL1515 - Eli Lilly and Company "
2017CG088ADVL1514 - A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
2017CG143COG ADVL1615 - A Phase I Study of Pevonedistat (MLN-4924, IND#136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
2017IS028Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNβ-NIS), in Patients with Refractory Solid Tumors
2017IS061MT2017-36 :FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
2017IS100HM2017-31: Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma
MT2009-09MT2009-09 Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation
NEURO-2016-24616A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy Who Participated in Study CN002003
NEUROSURG-2016-24894Extracorporeal Filtration of Subarachnoid Hemorrhage via Spinal Catheter
PEDS-2016-24779A Phase I, Multicenter, Open-label, Single-dose, Dose Ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis I (MPS I)
PEDS-2017-25493EXTRA-CORPOREAL LIFE SUPPORT RESEARCH DATABASE (PEDeCOR)
PEDS-2017-25617A Phase I, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913-1602, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPS II)
PSYCH-2016-18311Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers and Mechanisms
PSYCH-2017-26075Neuromodulation Augmented Cognitive Remediation to Improve Executive Function in Fetal Alcohol Syndrome